LM-24C5

N/A

Report date: 2025/11/05 20:01:16

Base Information

Drug NameLM-24C5

Drug Alias NameLM-24C5

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionTumor necrosis factor receptor superfamily member 9 activatorsAnti-CEACAM5

TargetsTumor necrosis factor receptor superfamily member 9Carcinoembryonic antigen related cell adhesion molecule 5

Therapy Area/IndicationsSolid tumoursNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesLaNova Medicines Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesLaNova Medicines Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A